Antipsychotics deprescribing in schizophrenia: trends and associated characteristics in Belgium and Québec
Background : Antipsychotic polypharmacy (APP) is common worldwide in schizophrenia, while switch to antipsychotic monotherapy reduces adverse effects. Canada has been the leader in deprescribing policies in the last decades. Aims : To detect factors, including countries, associated with successful antipsychotic deprescribing after a psychiatric hospitalisation. Methods : Retrospective data were collected in a tertiary care hospital in Montreal (QC, Canada) and compared to data collected in 6 Belgian hospitals, in 2020-2021. Adult inpatients with a diagnosis of schizophrenia or schizoaffective... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | conferenceObject |
Erscheinungsdatum: | 2022 |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-28553211 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://hdl.handle.net/2078.1/265775 |